TP53 and neoplasm: Among the 27 cases in the neoadjuvant cohort, with FFPE tumor samples available, 15 had pathogenic mutations (55%), and in two cases, two mutations were detected; 8/15 patients (53.3%) had alterations in the PIK3CA, 7/15 (46.6%) in the TP53, and 1/15 (6.6%) in the AKT1 and ESR1 genes.